[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-small-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-small-cell":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100477701","phase-2-assessment-of-compliance-with-monitoring-conducted-by-a-physician-in-person-or-by-a-nurse-in-remote-monitoring-100477701",false,"NCT05500391","Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring","Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring","SUR-CAN","Inclusion Criteria:\n\n* Positive diagnosis (anatomopathology) of tumor within 12 months\n* Patient 18 years of age or older\n* Patient with one of the following conditions:\n\n  1. Desmoid fibromatosis of the abdominal wall operated on or under active surveillance\n  2. Stage I testicular seminoma (whether or not treated with carboplatin AUC7)\n  3. Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)\n  4. Operated GIST with low risk of relapse\n  5. Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated\n  6. Low-grade glioma, operated\n  7. Low-grade neuroendocrine tumor, treated by surgery alone\n* Patient who has given consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindication to imaging tests required for the surveillance plan\n* No telephone\n* Patient under guardianship or curatorship","ALL","18 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (\\\u003C12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Stage I Testicular Seminoma","Stage I Testicular Nonseminomatous Germ Cell Tumor","Gastrointestinal Stromal Tumors","Ovarian Germ Cell Tumor","Adenocarcinoma, Clear Cell","Borderline Ovarian Tumor","Sex Cord-Stromal Tumor","Mucinous Adenocarcinoma of Ovary","Carcinoma, Small Cell","Carcinosarcoma, Ovarian","Serous Tumor of Ovary","Glioma","Neuroendocrine Tumors","Aggressive Fibromatosis of Abdominal Wall (Disorder)","RECRUITING","2026-03-16",{"date":44,"type":45},"2026-03-18","ACTUAL",{"date":47,"type":45},"2024-02-28",{"date":49,"type":21},"2032-07",{"name":51,"class":52},"Centre Oscar Lambret","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100605389","alg-lungcancerregistry-safro2202-100605389","NCT07161882","ALG-LungCancerRegistry (SAFRO2202)","Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.","SAFRO2202","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)\n* Diagnosed at the time of inclusion or within the 12 previous months\n* Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public\u002Funiversity hospitals\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Prior enrollment in this study\n* Participation in an interventional clinical trial",{"count":63,"type":21},3750,"12 Months","OBSERVATIONAL","SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.\n\nEligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required.\n\nThe study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS).\n\nThe findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.",[68,69,35,70],"Lung Neoplasms","Carcinoma, Non-Small-Cell Lung","Carcinoid Tumor",[72,73,70,74,75,76,77],"Lung Cancer","Non-Small Cell Lung Cancer","Treatment Outcomes","Drug-Related Side Effects","Registries","Algeria","2025-09-12",{"date":80,"type":45},"2025-09-16",{"date":82,"type":45},"2025-06-01",{"date":84,"type":21},"2027-12",{"name":86,"class":52},"Société Algérienne de Formation et de Recherche en Oncologie",21]